FDA Approves Foundayo (Orforglipron) — First Oral GLP-1 for Weight Loss With No Food or Water Restrictions
The FDA approved Eli Lilly’s Foundayo (orforglipron) on April 1, 2026, making it the first oral GLP-1 receptor agonist for […]
NPR Investigates Unregulated Peptides Sold Directly from Chinese Factories
An NPR/WBUR investigation published March 24 documented the pipeline through which unregulated peptides move from Chinese manufacturing facilities to American
Retatrutide Phase 3 Delivers 26% Weight Loss — But a New Safety Signal Emerges
Eli Lilly’s retatrutide — the first triple-hormone-receptor agonist (GLP-1, GIP, and glucagon) — posted striking Phase 3 results from the TRIUMPH program,
FDA Approves Icotyde — First Targeted Oral Peptide for Psoriasis
The FDA approved Icotyde (icotrokinra) on March 18, 2026, for moderate-to-severe plaque psoriasis in adults and adolescents aged 12 and
FDA Sharpens Enforcement on Compounded GLP-1 Drugs as Shortage Era Ends
The FDA has publicly signaled its intent to take enforcement action against non-approved GLP-1 drugs — a shift that follows the
Two New Systematic Reviews Confirm BPC-157’s Preclinical Promise — and Its Human Evidence Gap
Two recently published reviews have mapped the full landscape of BPC-157 research — and the picture they paint is simultaneously impressive
HHS Announces Peptide Reclassification — 14 Compounds Returning to Legal Compounding
On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 of the 19 peptides previously placed
Novo Nordisk’s CagriSema Fails to Beat Tirzepatide in Head-to-Head Trial
Novo Nordisk’s next-generation weight-loss candidate CagriSema — a fixed-ratio combination of semaglutide and the amylin analog cagrilintide — failed to demonstrate superiority
MIT Technology Review: “Peptides Are Everywhere. Here’s What You Need to Know.”
MIT Technology Review published a feature on February 23 documenting what anyone in the peptide space already knew — and what
Wegovy Pill Launches — Oral Semaglutide Now Available for Weight Management
Novo Nordisk’s Wegovy pill — oral semaglutide at 25 mg, once daily — became commercially available in January 2026, following FDA approval in